Zydus Lifesciences Limited
https://www.zyduslife.com/index
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Zydus Lifesciences Limited
US Court Provides Opportunity For Lupin And Zydus To Debut Generic Myrbetriq
Lupin and Zydus are targeting a market worth at least $1bn a year – and more than $2.4bn all told – after both in quick succession announcing the launch of generic versions of Astellas Pharma’s Myrbetriq treatment for overactive bladder.
A Myrbetriq Battle Is Brewing And Why It Matters
Zydus and Lupin are gearing up for the US launch of a generic to Astellas Pharma’s blockbuster drug Myrbetriq (mirabegron) while Aurobindo expects a longer wait. Meanwhile, Torrent is preparing to defend its market share in chronic therapies in India as other companies increasingly target this segment
Data Exclusivity Demand In EFTA-India Deal: Access, Licensing, Other Implications
The contentious issue of data exclusivity came to the fore during the European Free Trade Association's negotiations with India for a Free Trade Agreement. What are the arguments in support and against, including impact on compulsory and voluntary licensing?
Data Exclusivity Demand In EFTA-India Deal: Access, Licensing, Other Implications
The contentious issue of data exclusivity came to the fore during the European Free Trade Association's negotiations with India for a Free Trade Agreement. What are the arguments in support and against, including impact on compulsory and voluntary licensing?
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
-
- Cadila Healthcare
- Zydus Pharmaceuticals USA
- German Remedies
- Zynesher Pharmaceuticals USA LLC
- Nesher Pharmaceuticals Inc
- Quimica e Farmaceutica Nikkho do Brasil Ltda
- Bremer Pharma GmbH
- Nippon Universal Pharmaceuticals
- Zydus Discovery DMCC
- Zydus Urosciences
- Sentynl Therapeutics, Inc
- Zydus Lifesciences Ltd
- Cadila Healthcare Ltd.
- Zydus Cadila
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice